Table 2.
Multivariable analysis for discontinuation of active surveillance
| HR | 95% CI | p value | |
|---|---|---|---|
| Year of diagnosis | |||
| 2003 | 1.00 | Ref. | |
| 2004 | 0.61 | 0.45–0.81 | <0.001 |
| 2005 | 0.69 | 0.52–0.90 | 0.007 |
| 2006 | 0.89 | 0.69–1.14 | 0.3 |
| 2007 | 0.96 | 0.75–1.25 | 0.8 |
| Age, yr | |||
| <60 | 1.00 | Ref. | |
| 60–64 | 0.94 | 0.76–1.16 | 0.5 |
| 65–70 | 0.69 | 0.55–0.85 | <0.001 |
| Clinical T stage | |||
| ≤T1c | 1.00 | Ref. | |
| T2 | 1.63 | 1.32–2.02 | <0.001 |
| Biopsy Gleason score | |||
| ≤6 | 1.00 | Ref. | |
| 7 | 1.27 | 0.94–1.73 | 0.1 |
| Serum PSA | 1.01 | 1.00–1.01 | <0.001 |
| Comorbidity | 0.86 | 0.75–0.98 | 0.02 |
| Marital status | |||
| Single | 1.00 | Ref. | |
| Married | 1.00 | 0.84–1.19 | 1 |
| Education | |||
| Low | 1.00 | Ref. | |
| Middle | 1.16 | 0.96–1.41 | 0.1 |
| High | 1.45 | 1.17–1.80 | <0.001 |
CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen; Ref. = reference.